Blood pressure drugs don't protect against colorectal cancer

May 14, 2012

A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that even long-term use or subtypes of beta blockers showed no reduction of colorectal cancer risk.

In recent years, researchers have thought that beta blockers, which are prescribed to many older adults for high blood pressure and heart conditions, might be linked with a decreased risk of cancer. This theory stems from animal and laboratory studies that found that the stress hormone norepinephrine can promote the growth and spread of . Beta blockers inhibit norepinephrine's action, so it stands to reason that the medications could have anticancer properties.

Previous studies on beta blockers' effects on colorectal have yielded inconsistent results. To provide more thorough information, Michael Hoffmeister, PhD, of the German Cancer Research Center, in Heidelberg, Germany, and his colleagues conducted personal interviews from 2003 to 2007 with 1,762 patients with colorectal cancer and 1,708 cancer-free individuals.

After taking into consideration certain patient characteristics (such as weight and smoking status) and other factors that might influence the results, the researchers found no link between beta blocker use and colorectal cancer risk. Previous studies had not taken these factors into consideration. Even when the investigators broke down their analyses by duration of use of beta blockers, specific types of beta blockers, active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol), and sites within the colon or rectum where colorectal cancer developed, there was no link.

Overall, the results of this study do not support the hypothesis that using beta blockers can lower one's risk. The findings also point to the importance of considering patient characteristics and other factors that might influence the results of studies that look at how medications affect patients' cancer risk.

Explore further: Beta Blockers could stop breast cancer spreading

More information: “Beta blocker use and colorectal cancer risk: population-based case-control study.” Lina Jansen, Janina Below, Jenny Chang-Claude, Hermann Brenner, and Michael Hoffmeister. CANCER; Published Online: May 14, 2012 (DOI: 10.1002/cncr.26727).

Related Stories

Beta Blockers could stop breast cancer spreading

September 30, 2011
(Medical Xpress) -- Cancer Research UK scientists are investigating whether beta-blockers hold the key to preventing breast cancer spread and improving survival. Promising early results will be presented on the eve of breast ...

Recommended for you

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival

August 22, 2017
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...

Study identifies miR122 target sites in liver cancer and links a gene to patient survival

August 22, 2017
A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, ...

Zebrafish larvae could be used as 'avatars' to optimize personalized treatment of cancer

August 21, 2017
Portuguese scientists have for the first time shown that the larvae of a tiny fish could one day become the preferred model for predicting, in advance, the response of human malignant tumors to the various therapeutic drugs ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...

Searching for the 'signature' causes of BRCAness in breast cancer

August 21, 2017
Breast cancer cells with defects in the DNA damage repair-genes BRCA1 and BRCA2 have a mutational signature (a pattern of base swaps—e.g., Ts for Gs, Cs for As—throughout a genome) known in cancer genomics as "Signature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.